VKTX7:05 AMViking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with ObesityTrial StartTrial initiation Tue, Oct 6, 2026vikingtherapeutics.com
VKTX4:30 PMViking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notesvikingtherapeutics.com
VKTX7:05 AMViking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notesvikingtherapeutics.com
VKTX4:32 PMViking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notesvikingtherapeutics.com
VKTX7:05 AMViking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing RegimensTrial Results • Phase 2Topline results Tue, Sep 22, 2026, 8:00 AM ETGvikingtherapeutics.com
VKTX4:05 PMViking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateEnrollment • Phase 3Enrollment milestone Tue, Jun 30, 2026vikingtherapeutics.com
VKTX4:05 PMViking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026vikingtherapeutics.com